Market OpportunityAnalyst is moving to the sidelines based on a combination of factors including the relatively small market opportunity, regulatory uncertainty, and safety concerns with targeting CTLA-4.
Regulatory UncertaintyRegulatory uncertainty is a concern as another company is testing a similar immunotherapy combination for a similar treatment.
Tolerability ChallengesThere are tolerability challenges despite the potential of anti-CTLA-4 approaches to drive tumor responses.